Measuring the economic burden of breast cancer in middle-income countries: Protocol for a prospective cohort study in India and Kenya
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Gaps in health financing drive delayed diagnosis, catastrophic health expenditure, treatment discontinuation, and excess mortality and morbidity in breast cancer, effects compounded by gender inequalities that shape household resource allocation, care-seeking behaviour, and spending decisions for conditions disproportionately affecting women. Despite this, the economic burden of breast cancer and the gender dynamics that mediate it remain poorly characterised in middle-income country settings. This study examines the economic burden of breast cancer in India and Kenya and assesses how gender inequalities shape treatment decision-making, health outcomes, and caregiving experiences.
Methods
This will be a mixed-methods, longitudinal, prospective cohort study of newly diagnosed breast cancer patients, with a health economics and gender analysis. Participants will be surveyed twice, at baseline and 6-months post treatment commencement either in person or by phone. A sub-sample of participants and their caregivers will participate in semi-structured interviews to explore household economic consequences of treatment, treatment-seeking decisions, and the gendered dimensions of both. Quantitative data will be analysed using descriptive statistics and regression modelling to identify determinants of catastrophic health expenditure and economic burden. Thematic analysis will be conducted and triangulated with quantitative findings to provide a comprehensive account of financial and gendered impacts across both settings.
Discussion
The study will generate comparative evidence on the economic burden of breast cancer across two developing health system contexts. Findings will inform priority setting and benefit package design by identifying the drivers of economic burden and treatment discontinuation in these contexts, and making visible the household and caregiving costs that financing policy rarely captures.
